Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lipocine ( (LPCN) ) has shared an announcement.
On September 5, 2025, Lipocine Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference held from September 8-10, 2025, in New York City. The event provides Lipocine an opportunity to present its innovative oral delivery products and engage with investors, potentially impacting its market presence and stakeholder relationships.
The most recent analyst rating on (LPCN) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.
Spark’s Take on LPCN Stock
According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.
Lipocine’s overall stock score is driven by a strong balance sheet and positive corporate developments, which are offset by ongoing profitability challenges and bearish technical indicators. The company’s active pipeline and strategic initiatives offer potential upside, but financial and valuation concerns remain significant.
To see Spark’s full report on LPCN stock, click here.
More about Lipocine
Lipocine Inc. is a biopharmaceutical company that utilizes its proprietary technology platform to develop innovative oral delivery products. The company focuses on drug candidates that offer patient-friendly oral delivery options targeting large markets with unmet medical needs. Lipocine’s clinical development pipeline includes treatments for postpartum depression, epilepsy, essential tremor, obesity management, and liver cirrhosis, among others. TLANDO, an oral prodrug of testosterone, is FDA-approved for treating hypogonadism in adult males.
Average Trading Volume: 38,728
Technical Sentiment Signal: Sell
Current Market Cap: $15.66M
For detailed information about LPCN stock, go to TipRanks’ Stock Analysis page.